Health seeking behavior of in pulmonary tuberculosis patients during COVID-19 pandemic and lockdown in a tertiary care center


  • Arivudai Nambi Veerappan Periasamy Department of Respiratory Medicine, KAPV and MGM Medical college Hospital Tiruchirappalli, Tamil Nādu, India
  • Yazhlini . Madurai Medical College, Madurai, Tamil Nādu, India



TB, TB and lockdown, TB in patients, Health behaviour


Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in India in 2020 having originated from China in late 2019. There is no study on the impact of covid management burden on tuberculosis (TB) management. Study on the effect of lockdown on TB management is also unknown. This is a pilot study.

Method: It is hypothesised that only people who are severely symptomatic will get tested for TB and severely sick patients will get admitted during the lockdown period. Data from outpatient TB clinic and inpatient ward were analysed.

Results: During the lockdown of 5 months saw severe fall in the attendance of the outpatient to 727 patients which was almost 44.44% of the pre lockdown patients, sputum positive among them were 160, positivity rate was 21.69. The total inpatients admission in the lockdown period of 6 months was 130 with average of 26 per month (36% of normal). The Wald chi-square for outpatient p=0.00 with CI=43.30-63.81. The Wald chi-square test for inpatient admission p=0.00 with CI=31.66-49.52. The results of inpatients admission showed that only sick and serious patients approached hospital in the lockdown period.

Conclusions: The results in the outpatient setting showed that mild to moderate symptomatic patients may not seek consultation only severe cases approached healthcare leading to spread.


Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-42.

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-13.

Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX. China Medical Treatment Expert Group for Covid-19 Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708-20.

Ong CWM, Goletti D. Impact of the global COVID-19 outbreak on the management of other communicable diseases. Int J Tuberc Lung Dis. 2020;24(5):547-8.

World Health Organization. Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV); Geneva, Switzerland: 2005. Statement on the second meeting of the International Health Regulations. 2020.

Stop TB Partnership, Imperial College, Avenir Health, Johns Hopkins University, and USAID. The Potential Impact of the COVID-19 Response on Tuberculosis in High-Burden Countries: A Modelling Analysis. Available at: https://stoptb. org/assets/documents/news/Modeling%20Report_1%20May%202020_FINAL.pdf. Accessed on 25 January, 2023.

World Health Organization. World Health Organization; Geneva: 2020. Global tuberculosis report 2020. License: CC BY-NC-SA 3.0 IGO.

Cilloni L, Fu H, Vesga JF, Dowdy D, Pretorius C, Ahmedov S. The potential impact of the COVID-19 pandemic on the tuberculosis epidemic a modelling analysis. E-Clin Med. 2020;28.

Migliori GB, Thong PM, Akkerman O, Alffenaar JW, Álvarez-Navascués F, Assao-Neino MM. Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services, January-April 2020. Emerg Infect Dis. 2020;26(11):2709-12.

Buonsenso D, Iodice F, Sorba Biala J, Goletti D. COVID-19 effects on tuberculosis care in Sierra Leone. Pulmonology. 2021;27(1).

Tadolini M, Codecasa LR, García-García JM, Blanc FX, Borisov S, Alffenaar JW. Active tuberculosis, sequelae, and COVID-19 co-infection: first cohort of 49 cases. Eur Respir J. 2020;56(1).

Motta I, Centis R, D’Ambrosio L, García-García JM, Goletti D, Gualano G. Tuberculosis, COVID-19, and migrants: Preliminary analysis of deaths occurring in 69 patients from two cohorts. Pulmonology. 2020;26(4):233-40.

Stochino C, Villa S, Zucchi P, Parravicini P, Gori A, Raviglione MC. Clinical characteristics of COVID-19 and active tuberculosis co-infection in an Italian reference hospital. Eur Respir J. 2020;56(1).

Abdool Karim Q, Abdool Karim SS COVID-19 affects HIV and tuberculosis care. Science. 2020;369(6502):366-8.

Mandavilli A. The New York Times; 2020. ‘The biggest monster’ is spreading. And it is not the coronavirus.

Ong CWM, Migliori GB, Raviglione M, MacGregor-Skinner G, Sotgiu G, Alffenaar JW. Epidemic and pandemic viral infections: impact on tuberculosis and the lung: A consensus by the World Association for Infectious Diseases and Immunological Disorders (WAidid), Global Tuberculosis Network (GTN), and members of the European Society of Clinical Microbiology and Infectious Diseases Study Group for Mycobacterial Infections (ESGMYC) Eur Respir J. 2020;56(4).

Sheerin D, Abhimanyu Wang X, Johnson WE, Coussens A. Systematic evaluation of transcriptomic disease risk and diagnostic biomarker overlap between COVID-19 and tuberculosis: a patient-level meta-analysis. medRxiv. 2020;11.






Original Research Articles